

**PRESS RELEASE**

**ALFASIGMA AT UEG WEEK  
(Vienna, 12 -15 OCTOBER 2024)**

**Milano, 10 October 2024** - Alfasigma will present data at the United European Gastroenterology (UEG) Week 2024, one of the most important annual international conferences in this therapeutic area. It will take place from 12-15 October 2024 and Alfasigma will be based at booth 26 in Hall B.

During these days, several Alfasigma driven presentations and abstracts focused on ulcerative colitis and chronic intestinal pseudo-obstruction will be showcased.

This is the first congress in which Alfasigma is participating since becoming the marketing authorization holder for Jyseleca® in the European Union and Great Britain, Announced in August and September respectively. The market authorization transfers followed the [transaction completed on January 31, 2024](#), in which Alfasigma acquired the Jyseleca® (filgotinib) business from Galapagos NV. With this acquisition, the Italian pharmaceutical company consolidated its commitment to delivering innovative healthcare solutions across Europe and addressing critical unmet needs in the gastrointestinal field.

**Alfasigma Commitment in Gastroenterology**

This participation in UEG Week 2024 underlines Alfasigma’s commitment to Gastroenterology. In collaboration with the medical community and patient associations, Alfasigma strives to provide tangible and viable solutions to gastro-intestinal and liver disorders, ranging from prevalent diseases where gut microbiota plays an essential role, such as IBD (Inflammatory Bowel Disease), to functional disorders (e.g. IBS) like bacterial gastroenteritis, and gastro-esophageal reflux and liver rare diseases.

**UEG week abstracts and presentations include:**

<b>Abstract Title</b>	<b>Authors (<u>Presenter</u> if known)</b>	<b>Presentation date/time</b>
Long-term efficacy and safety of filgotinib 200 mg in ulcerative colitis: 5-year interim data from SELECTIONLTE	<u>Brian G. Feagan</u> , Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V. Loftus, Jr., Ian Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Alexandra Mangili, Christine Rudolph and Laurent Peyrin-Biroulet	<b><u>Oral presentation</u></b> Session: Maintaining remission and quality of life in IBD Date: 14.10.2024 Time: 14:30 - 15:30 Presentation number: OP105

<p>Early real-world outcomes with filgotinib in patients with ulcerative colitis: a prospective, observational study (GALOCEAN)</p>	<p><u>Mark Löwenberg</u>, John Paul Seenan, Marte Lie Høivik, Cyrielle Gilletta de Saint Joseph, Walter Reinisch, Alessandro Armuzzi, Stefan Schreiber, Elena Ricart, Glen Doherty, Roberto Saldaña, Will Sawyer, Anna Jus, Monia Zignani, and Séverine Vermeire</p>	<p><b><u>Moderated poster</u></b>          Session: JAK inhibitors in the treatment of IBD          Date: 14.10.2024          Time: 13:24 – 13:30          Poster number: MP330</p>
<p>Clinical symptom trajectories are supported by differential regulation of mucosal transcriptomes in patients with ulcerative colitis treated with filgotinib: a <i>post hoc</i> analysis of the SELECTION study</p>	<p><u>Stefan Schreiber</u>, Matthew Randall, Jonas Halfvarson, Florian Rieder, Peter Irving, Brian G Feagan, Laure Cougnaud, Alessandra Oortwijn, Yasmina Bauer, Walter Reinisch</p>	<p><b><u>Poster</u></b>          Poster topic: 5.: IBD (INCLUDING MICROSCOPIC COLITIS)          Poster number: PP0447</p>
<p>Comprehensive disease control in patients with ulcerative colitis: refinement of an individual, multi-component endpoint using data from the filgotinib SELECTION trial</p>	<p><u>Stefan Schreiber</u>, Brian G Feagan, Séverine Vermeire, Silvio Danese, Veerle Vyncke, Margaux Faes, Alessandra Oortwijn and Laurent Peyrin-Biroulet</p>	<p><b><u>Poster</u></b>          Poster topic: 5.: IBD (INCLUDING MICROSCOPIC COLITIS)          Poster number: PP0605</p>
<p>Safety and efficacy of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A phase II proof-of-concept study</p>	<p>Vincenzo Stanghellini, <u>Carolina Malagelada</u>, Roberto De Giorgio, Rosanna Francesca Cogliandro, Luis Alcala-Gonzalez, Anna Costanzini, Maria Grimaldi, Roberto Giovannini, Emanuela Gentile, Valeria Scuderi, Sara Manzoni, Elena Pasquali, Chiara Costantini, Michelangelo Barone, Andrea Pellacani and Jan Tack</p>	<p><b><u>Moderated poster</u></b>          Session: Potpourri of DGBI and motility          Date: 13.10.2024          Time: 12:00 - 13:00          Poster number: MP057</p>



**About Chronic Intestinal Pseudo-Obstruction (CIPO)**

Chronic Intestinal Pseudo-Obstruction (CIPO) is a rare disease characterized by a severe impairment of intestinal propulsive activity resulting in a clinical picture mimicking a mechanical intestinal obstruction in the absence of any physical obstruction.

**About Ulcerative Colitis (UC)**

Ulcerative colitis is an inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the digestive tract. Ulcerative colitis affects the innermost lining of the large intestine, also called the colon, and rectum and it is an increasingly prevalent inflammatory disease that causes disruptive symptoms and reduced HRQoL. Despite therapy, many patients with UC continue to use corticosteroids and experience insufficient disease control.

**About Alfasigma**

Alfasigma is one of the leading Italian pharmaceutical companies, operating in over 100 countries worldwide with approximately 4,000 employees dedicated to research, development, production, and distribution. With more than 75 years of history, the Company has a longstanding track record in developing innovative therapeutic indications to meet the new needs of patients while renewing and consolidating its existing products. Its mission is to improve people's health and quality of life by offering caregivers and healthcare personnel therapeutic solutions according to the highest standards of quality and safety. Alfasigma has a strong focus in the gastro-intestinal therapeutic area and worldwide has products also in vascular and rheumatology. As part of its strategy to expand its specialty care portfolio in gastroenterology and rheumatology, Alfasigma strengthened its international presence with targeted acquisitions in US and Europe. For more information, visit the Company website at [www.alfasigma.com](http://www.alfasigma.com) or connect with the Company on [LinkedIn](#)